A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Brief description of study

The Study is two research trials aimed at preventing Alzheimer’s disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. AHEAD-3 studies people with intermediate amyloid, while AHEAD-45 studies people with elevated amyloid. Research studies are designed to gain scientific knowledge that may help people in the future.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Preclinical Alzheimer's diseaseElevated amyloidEarly preclinical Alzheimer's disease
Age: Between 55 Years - 80 Years
Gender: All

Male or female, age 55 to 80 years inclusive Study Partner

Updated on 09 Mar 2024. Study ID: 842728

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).